How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Small-Molecule Library Screening by Docking with PyRx
Dallakyan, S., & Olson, A. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2269-7_19 · Cited by 3,998
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
From 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Zebrafish as tools for drug discovery
MacRae, C. A., & Peterson, R. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4627 · Cited by 1,204
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Natural product discovery: past, present, and future
Katz, L., & Baltz, R. H. (2016) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-015-1723-5 · Cited by 1,144
Target identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Bray, M.-A., Singh, S., Han, H., Davis, C. T., Borgeson, B., Hartland, C., Kost-Alimova, M., Gustafsdottir, S. M., Gibson, C. C., & Carpenter, A. E. (2016) · Nature Protocols · doi:10.1038/nprot.2016.105 · Cited by 1,090
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B., Cheah, J. H., Adams, D. J., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V. L., Bodycombe, N. E., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 898
Three-Dimensional Cell Cultures in Drug Discovery and Development
Fang, Y., & Eglen, R. M. (2017) · SLAS Discovery · doi:10.1177/1087057117696795 · Cited by 849
A Structure-Based Drug Discovery Paradigm
Batool, M., Ahmad, B., & Choi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112783 · Cited by 744
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Najmi, A., Javed, S. A., Al Bratty, M., & Alhazmi, H. A. (2022) · Molecules · doi:10.3390/molecules27020349 · Cited by 596
Review of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Gerwick, W. H., & Moore, B. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.014 · Cited by 601
The pharmaceutical industry and natural products: historical status and new trends
David, B., Wolfender, J.-L., & Dias, D. A. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-014-9367-z · Cited by 579
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping
Wu, Y., Zhang, F., Yang, K., Fang, S., Bu, D., Li, H., Sun, L., Hu, H., Gao, K., Wang, W., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1021 · Cited by 561
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
WILDS: A Benchmark of in-the-Wild Distribution Shifts
Koh, P. W., Sagawa, S., Marklund, H., Xie, S. M., Zhang, M., Balsubramani, A., Hu, W., Yasunaga, M., Phillips, R. L., Gao, I., et al. (2020) · arXiv · doi:10.48550/arxiv.2012.07421 · Cited by 518
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 466
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Ligand and Target Discovery by Fragment-Based Screening in Human Cells
Parker, C. G., Galmozzi, A., Wang, Y., Correia, B. E., Sasaki, K., Joslyn, C. M., Kim, A. S., Cavallaro, C. L., Lawrence, R. M., Johnson, S. R., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.029 · Cited by 439
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 436
Drug repurposing from the perspective of pharmaceutical companies
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13798 · Cited by 429
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 423
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
Swinney, D. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.236 · Cited by 413
Self-citationJin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Selective small-molecule inhibition of an RNA structural element
Howe, J. A., Wang, H., Fischmann, T. O., Balibar, C. J., Xiao, L., Galgoci, A. M., Malinverni, J. C., Mayhood, T., Villafania, A., Nahvi, A., et al. (2015) · Nature · doi:10.1038/nature15542 · Cited by 407
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
High-Throughput Screening: today’s biochemical and cell-based approaches
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.024 · Cited by 387
Image-based profiling for drug discovery: due for a machine-learning upgrade?
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D., & Carpenter, A. E. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00117-w · Cited by 389
Computational Drug Repositioning: From Data to Therapeutics
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.1 · Cited by 373
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Little Fish, Big Data: Zebrafish as a Model for Cardiovascular and Metabolic Disease
Gut, P., Reischauer, S., Stainier, D. Y. R., & Arnaout, R. (2017) · Physiological Reviews · doi:10.1152/physrev.00038.2016 · Cited by 333
Huigens III, R. W., Morrison, K. C., Hicklin, R. W., Flood Jr, T. A., Richter, M. F., & Hergenrother, P. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1549 · Cited by 320
3D bioprinting for drug discovery and development in pharmaceutics
Peng, W., Datta, P., Ayan, B., Ozbolat, V., Sosnoski, D., & Ozbolat, I. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.025 · Cited by 313
The strategies and techniques of drug discovery from natural products
Zhang, L., Song, J., Kong, L., Yuan, T., Li, W., Zhang, W., Hou, B., Lu, Y., & Du, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107686 · Cited by 313
Utilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Antimalarial drug discovery — approaches and progress towards new medicines
Flannery, E. L., Chatterjee, A. K., & Winzeler, E. A. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3138 · Cited by 313
Kim, J., Kim, H., & Park, S. B. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508343a · Cited by 308
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms
Kirchmair, J., Williamson, M. J., Tyzack, J. D., Tan, L., Bond, P. J., Bender, A., & Glen, R. C. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200542m · Cited by 289
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L. (2012) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2012.01.003 · Cited by 294
Changing R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Revealing the structure of pharmacobehavioral space through motion sequencing
Wiltschko, A. B., Tsukahara, T., Zeine, A., Anyoha, R., Gillis, W. F., Markowitz, J. E., Peterson, R. E., Katon, J., Johnson, M. J., & Datta, S. R. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00706-3 · Cited by 298
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
Systematic Drug Repositioning Based on Clinical Side-Effects
Yang, L., & Agarwal, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028025 · Cited by 266
15 years of zebrafish chemical screening
Rennekamp, A. J., & Peterson, R. T. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.025 · Cited by 264
Stimulated Raman scattering microscopy: an emerging tool for drug discovery
Tipping, W. J., Lee, M., Serrels, A., Brunton, V. G., & Hulme, A. N. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00693g · Cited by 266
Bioinformatics and Drug Discovery
Xia, X. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666161116143440 · Cited by 252
Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives
Melo, A., Monteiro, L., Lima, R. M. F., de Oliveira, D. M., de Cerqueira, M. D., & El-Bachá, R. S. (2011) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2011/467180 · Cited by 249
Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in Neurons
Tardiff, D. F., Jui, N. T., Khurana, V., Tambe, M. A., Thompson, M. L., Chung, C. Y., Kamadurai, H. B., Kim, H. T., Lancaster, A. K., Caldwell, K. A., et al. (2013) · Science · doi:10.1126/science.1245321 · Cited by 251
Contribution of NIH funding to new drug approvals 2010–2016
Galkina Cleary, E., Beierlein, J. M., Khanuja, N. S., McNamee, L. M., & Ledley, F. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715368115 · Cited by 248
In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors
Guillen Schlippe, Y. V., Hartman, M. C. T., Josephson, K., & Szostak, J. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301017y · Cited by 239
Strategies for the Diversity-Oriented Synthesis of Macrocycles
Mortensen, K. T., Osberger, T. J., King, T. A., Sore, H. F., & Spring, D. R. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00084 · Cited by 234
Kiriiri, G. K., Njogu, P. M., & Mwangi, A. N. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00047-9 · Cited by 227
Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis
Llabani, E., Hicklin, R. W., Lee, H. Y., Motika, S. E., Crawford, L. A., Weerapana, E., & Hergenrother, P. J. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0261-6 · Cited by 230
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Convertible visceral fat as a therapeutic target to curb obesity
Giordano, A., Frontini, A., & Cinti, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.31 · Cited by 232
Olayan, R. S., Ashoor, H., & Bajic, V. B. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx731 · Cited by 231
Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds
Hitchcock, S. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201136z · Cited by 217
Idée, J.-M., & Guiu, B. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.003 · Cited by 227
Azizgolshani, H., Coppeta, J. R., Vedula, E. M., Marr, E. E., Cain, B. P., Luu, R. J., Lech, M. P., Kann, S. H., Mulhern, T. J., Tandon, V., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00067e · Cited by 225
Thota, S., Rodrigues, D. A., Pinheiro, P. D. S. M., Lima, L. M., Fraga, C. A. M., & Barreiro, E. J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.015 · Cited by 222
Compilation of 222 drugs’ plasma protein binding data and guidance for study designs
Zhang, F., Xue, J., Shao, J., & Jia, L. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.018 · Cited by 220
Harvey, A. L. (2014) · Toxicon · doi:10.1016/j.toxicon.2014.10.020 · Cited by 210
Increasing the Content of High-Content Screening: An Overview
Singh, S., Carpenter, A. E., & Genovesio, A. (2014) · SLAS Discovery · doi:10.1177/1087057114528537 · Cited by 215
DrugNet: Network-based drug–disease prioritization by integrating heterogeneous data
Martínez, V., Navarro, C., Cano, C., Fajardo, W., & Blanco, A. (2015) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2014.11.003 · Cited by 214
Current understanding of the mechanism of action of the antiepileptic drug lacosamide
Rogawski, M. A., Tofighy, A., White, H. S., Matagne, A., & Wolff, C. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.11.021 · Cited by 208
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
Chu, Y., Kaushik, A. C., Wang, X., Wang, W., Zhang, Y., Shan, X., Salahub, D. R., Xiong, Y., & Wei, D.-Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz152 · Cited by 208
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology
Blagg, J., & Workman, P. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.005 · Cited by 203
Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery
Kumar, A., & Zhang, K. Y. J. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00315 · Cited by 202
Developing predictive assays: The phenotypic screening “rule of 3”
Vincent, F., Loria, P., Pregel, M., Stanton, R., Kitching, L., Nocka, K., Doyonnas, R., Steppan, C., Gilbert, A., Schroeter, T., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1201 · Cited by 199
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
McLure, K. G., Gesner, E. M., Tsujikawa, L., Kharenko, O. A., Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083190 · Cited by 198
Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery
Garcia‐Castro, M., Zimmermann, S., Sankar, M. G., & Kumar, K. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201508818 · Cited by 199
Gilbert, I. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400362b · Cited by 190
Leishmaniasis drug discovery: recent progress and challenges in assay development
Zulfiqar, B., Shelper, T. B., & Avery, V. M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.004 · Cited by 196
Drug discovery through stem cell-based organoid models
Ranga, A., Gjorevski, N., & Lutolf, M. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.006 · Cited by 195
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., & Sall, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201649s · Cited by 192
Chung, C.-W., Dean, A. W., Woolven, J. M., & Bamborough, P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201320w · Cited by 188
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
Systematic Targeting of Protein–Protein Interactions
Modell, A. E., Blosser, S. L., & Arora, P. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.008 · Cited by 184
Ljosa, V., Caie, P. D., ter Horst, R., Sokolnicki, K. L., Jenkins, E. L., Daya, S., Roberts, M. E., Jones, T. R., Singh, S., Genovesio, A., et al. (2013) · SLAS Discovery · doi:10.1177/1087057113503553 · Cited by 186
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.